Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Presse Medicale (Paris, France : 1983)|May 12, 2015
[Vitamin D deficiency prediction by patient questionnaire and secondary hyperparathyroidism in a cohort of 526 healthy subjects in their fifties]Michel Laroche, Delphine Nigon, Isabelle Gennero, et al.Clinical Immunology (Orlando, Fla.)|July 14, 2018
Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseasesEric Espinosa, Salvatore Valitutti, Michel Laroche, et al.Bone|October 11, 2017
DKK1 and sclerostin are early markers of relapse in multiple myelomaCharlotte Mabille, Adeline Ruyssen-Witrand, Yannick Degboe, et al.Bone Reports|March 7, 2022
Diagnostic yield of bone fragility gene panel sequencing in children and young adults referred for idiopathic primary osteoporosis at a single regional reference centreColine Rouleau, Margaux Malorie, Corinne Collet, et al.Joint Bone Spine|January 8, 2011
Severe osteoporosis: diagnosis and follow-up. Lessons for clinical practiceChristian Roux, Cyrille B Confavreux, Bernard Cortet, et al.The Journal of Allergy and Clinical Immunology. in Practice|February 29, 2024
The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis PatientsYannick Degboé, Maella Severino-Freire, Guillaume Couture, et al.Bone|September 19, 2017
Prevalence and risk factors for fragility fracture in systemic mastocytosisYannick Degboé, Marine Eischen, Delphine Nigon, et al.Joint Bone Spine|December 3, 2014
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosisKarine Briot, Bernard Cortet, Christian Roux, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 12, 2013
Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal womenYohann Bala, Roland Chapurlat, Angela M Cheung, et al.Journal of the American Academy of Dermatology|February 23, 2016
Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvementMaella Severino, Marie-Olivia Chandesris, Stéphane Barete, et al.Pageof 6